CVS Health price target lowered to $90 from $91 at Argus

Argus lowered the firm’s price target on CVS Health (CVS) to $90 from $91 but keeps a Buy rating on the shares. The stock declined by close to 15% after the Centers for Medicare and Medicaid Services proposed a flat 2027 Medicare Advantage reimbursement rate over 2026, but the firm sees this rate as likely to be revised upward before final implementation in April 2026, the analyst tells investors in a research note, adding that should the final rate increase come in lower than the prior year’s 5.1% increase, CVS’s diversification should be able to mitigate the impact compared to pure play health insurers.